Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | -6.28% | +12.91% | -0.56% |
02:43pm | Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating | MT |
May. 06 | Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.56% | 93.66M | |
+20.95% | 46.81B | |
-0.83% | 41.37B | |
+47.19% | 41.29B | |
-6.20% | 28.87B | |
+10.75% | 26.06B | |
-20.69% | 19.13B | |
+31.14% | 12.39B | |
+0.19% | 12.08B | |
-0.45% | 11.96B |
- Stock Market
- Equities
- CRVS Stock
- News Corvus Pharmaceuticals, Inc.
- Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target